ABIVAX Société Anonyme (NASDAQ:ABVX) Receives $38.67 Average Target Price from Analysts

ABIVAX Société Anonyme (NASDAQ:ABVX) has received a consensus recommendation of “Buy” from the seven analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $38.67.

A number of equities analysts have recently weighed in on the company. JMP Securities reiterated a “market outperform” rating and set a $33.00 price target on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th.

ABIVAX Société Anonyme Stock Up 0.3 %

Shares of ABVX opened at $5.94 on Friday. ABIVAX Société Anonyme has a 52-week low of $5.50 and a 52-week high of $17.02. The stock has a fifty day simple moving average of $6.72 and a two-hundred day simple moving average of $8.70.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC purchased a new stake in shares of ABIVAX Société Anonyme in the fourth quarter valued at approximately $29,000. R Squared Ltd acquired a new stake in ABIVAX Société Anonyme in the fourth quarter valued at $36,000. Bank of America Corp DE grew its holdings in ABIVAX Société Anonyme by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in ABIVAX Société Anonyme in the fourth quarter valued at $85,000. Finally, Guggenheim Capital LLC acquired a new stake in ABIVAX Société Anonyme in the fourth quarter valued at $92,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.